drugset / Trial / NCT06568328
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory/resistant or steroid-dependent GVHD.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-01-01
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNK-UT | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | CNK-UT | Cell therapy | 1e+08 cells/kg | Intravenous |